ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial
The ADELE clinical trial seeks to improve outcomes for people with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy. It is hoped that this study may improve relapse rates in high-risk endometrial cancer by adding Tislelizumab immunotherapy to standard treatment.
Primary Sponsor
ANZGOG
Collaborating Groups
TROG Cancer Research
Trial Chairperson
Professor Linda Mileshkin, Peter MacCallum Cancer Centre
Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital
Trial Contact
qa@trog.com.au
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
